Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Short term Debt (2020 - 2024)

Historic Short term Debt for Syndax Pharmaceuticals (SNDX) over the last 5 years, with Q4 2024 value amounting to $12.1 million.

  • Syndax Pharmaceuticals' Short term Debt changed N/A to $12.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $12.1 million, marking a year-over-year change of. This contributed to the annual value of $12.1 million for FY2024, which is N/A changed from last year.
  • Per Syndax Pharmaceuticals' latest filing, its Short term Debt stood at $12.1 million for Q4 2024.
  • Syndax Pharmaceuticals' 5-year Short term Debt high stood at $12.1 million for Q4 2024, and its period low was $187000.0 during Q4 2021.
  • In the last 4 years, Syndax Pharmaceuticals' Short term Debt had a median value of $5.8 million in 2021 and averaged $5.8 million.
  • As far as peak fluctuations go, Syndax Pharmaceuticals' Short term Debt plummeted by 9181.62% in 2021, and later surged by 258.89% in 2022.
  • Quarter analysis of 4 years shows Syndax Pharmaceuticals' Short term Debt stood at $2.3 million in 2020, then crashed by 91.82% to $187000.0 in 2021, then surged by 3756.68% to $7.2 million in 2022, then surged by 68.0% to $12.1 million in 2024.
  • Its Short term Debt was $12.1 million in Q4 2024, compared to $7.2 million in Q2 2022 and $3.6 million in Q1 2022.